Regenicin, Inc. (RGIN) is a biotechnology company developing regenerative cell therapies. The stock price closed at $0.70 on January 31, 2011, down 271% from its 52-week high. The company has no revenue, recurring losses, and may face liquidity issues that could threaten its operations. Technical analysis indicates the stock price has been in a downtrend and could continue to decline.

1. Hotstocked.com Company Research
Regenicin, inc. (RGIN) Jan 31, 2011
Summary
Share Price Summary Overview Percent Price Change RGIN S&P 500
Close Price on Jan 31, 2011.................................... 0.70 Volume on Jan 31, 2011.................................... 129,050 Year To Date............................... 16.67.................. -100
Off 52-Week Low................................................... 40% Avg Vol (3m).................................................... 238,489 One Year........................................ N/A.................. N/A
Over 52-Week High........................................ -271.43% Market Cap................................................... 51,720,000 Two Years...................................... N/A.................. N/A
52-Week low........................................................... 0.42 TTM Price/Earnings................................................ N/A Three Years.................................... N/A.................. N/A
52-Week high.......................................................... 2.60 EPS (ttm)................................................................ -0.01 Five Years...................................... N/A.................. N/A
Contact Info
Address: 10 HIGH COURT LITTLE FALLS NJ 07424 646-403-3581
Web Site: www.regenicin.com
Phone: 973-557-8914
Fax: N/A
Table of Contents
Performance Rating...................................................... 2 General Sentiment........................................................ 5
Getting Acquainted....................................................... 3 Description................................................................... 6
Share Liquidity............................................................. 4
Disclaimer
This research report is provided for informational purposes only and on the condition that it will not form the sole basis for any investment decision. Reference to
any company is not a recommendation to buy or sell the shares of such company. The information used for, or presented in, this report has been obtained from
sources believed to be reliable, but Hotstocked makes no representation as to the accuracy or completeness of such information. This report in intended only for
users in the United States. Hotstocked has no obligation to update, modify or amend this report or to otherwise notify a reader thereof in the event that any matter
stated herein becomes inaccurate. Hotstocked and/or its affiliates/investors may hold securities positions in the companies discussed in this report and may
frequently trade in such positions. Such investments may be inconsistent with the quantitative analysis provided in this report.
©Hotstocked 2008. All rights reserved. This report may not be reproduced, modified, distributed or published without the prior written authorization of Hotstocked.

2. Regenicin, inc. (OTCBB: RGIN) Hotstocked.com Company Research
Performance Rating: Sell
Hotstocked.com Composite Rating Component Rating 12 month Price Target
Unattractive: Risk Factors greatly outweigh any
merits we have found while conducting our
research on this company. We expect this stock
to decline and our recommendation to investors is
12 Month Price Target: $0.28
to sell any position that they have in this security.
Percentage Change: 60% Loss
"Under" = Underperform
Technical Analysis Component: Sell
Technical analysis is the study and analysis of trading patterns generated by market activity. While Technical Analysis can be useful at making short term
predictions, it ignores fundamental factors that may impact an entities value long term.
While there appears to be a market for RGIN stock it is certainly a very thin one. A small investor making an average sized investment would have the ability to
move this stock. Sometimes in markets such as this one the transaction costs based on the difference between the bid and ask can erode potential gains. RGIN
share prices have been a strong downtrend while selling pressure seems to have slowed, there are no indicators suggesting this stock will go higher. RGIN stock
has just formed a dangerous chart pattern breaking through support levels that can push the stock down further from here.
Very Negative Negative Neutral Positive Very Positive
Liquidity of Stock
Price Trend
Technical Breakout
Valuation Analysis: Sell
Valuation Analysis is a simple comparison of what the current market prices would represent to an acquirer of the company in relation to numerical aspects of their
business. This is useful at determining whether or not the stock is a good value. However stocks that are a good value often have negative operational trends and
good value on its own is not a convincing argument that a stock should be bought. Conversely stocks that are overvalued often have positive operational trends.
RGIN stock is currently priced at a standard market premium in relation to the sales the company generates it does not appear to be over or undervalued. RGIN
market value represents a higher than average premium to the assets in the company. They are a small company competing with larger competitors with greater
resources. Their ability to grow over the long term will be limited unless this situation is corrected.
Very Negative Negative Neutral Positive Very Positive
Price to Sales
Price to Book
Industry Strength
Fundamental Analysis: Strong Sell
This section is an analysis of this company's balance sheet in relation to their spending patterns and immediate and longer term needs
This company appears unable to meet bills that are either past due or will come due over the next 90 days. They are facing an immediate liquidity crisis. Which
can have a substantial adverse impact on share value. They are completely inadequately financed to execute any business plan. And in dire need of additional
funding. Given their weak position, this funding will most likely have a substantially adverse impact on existing shareholders. They are in an industry that is
extremely unpopular with investors right now, obtaining investment money will be quite difficult and it may come on extremely unfavorable terms.
Very Negative Negative Neutral Positive Very Positive
Current Cash Needs
Long Term Cash Needs
Industry Climate for funding
Operational Analysis: Strong Sell
This is an analysis of their business activities over the last 12 months and how this can impact the company and it's share price over the next year
Sales are substantially and rapidly declining. This company is losing money and the losses are getting bigger. They have negative margins meaning they are
selling their goods for a lower cost than that to produce them. This is not factoring in their fixed overhead. This can have an extreme negative impact on their
business and share price.
Very Negative Negative Neutral Positive Very Positive
Sales
Earnings
Margins
Jan 31, 2011 Page 2

3. Regenicin, inc. (OTCBB: RGIN) Hotstocked.com Company Research
Getting Acquainted
Business Summary
Regenicin, Inc. is a biotechnology company specializing in the development of and commercialization of regenerative cell therapies to
restore the health of damaged tissues and organs.
Financial Trends
in Thousands of Dollars
Fiscal Year Ending 09/2008 09/2009 09/2010 TTM
Operating Revenue N/A N/A N/A N/A
Cost of Revenue N/A N/A 251 251
Gross Operating Profit N/A N/A 251 251
EBITDA -44 -11 -428 -428
Total Net Income -44 -11 -935 -935
Diluted EPS from Total Operations N/A N/A -0.01 -0.01
Key Ratios
Fiscal Year Ending 09/2008 09/2009 09/2010 TTM
% Sales Growth N/A N/A N/A N/A
% EPS Growth N/A N/A N/A 0
% Gross Margin N/A N/A N/A N/A
% Return on Assets N/A N/A 0 8.3
% Return on Equity N/A N/A -1568.8 11.4
Peer Comparison
They are a small company competing with larger competitors with greater resources. Their ability to grow over the long term will be limited unless this situation is
corrected.
Jan 31, 2011 Page 3

4. Regenicin, inc. (OTCBB: RGIN) Hotstocked.com Company Research
Share Liquidity
RGIN stock is illiquid. A small amount of buying or selling can impact the price. Stocks that are this inactive are often the subject of market manipulation
strategies.
1 Year Price Chart
10 Year Price Chart 5 Year Price Chart
6 Month Price Chart 1 Month Price Chart
Jan 31, 2011 Page 4

5. Regenicin, inc. (OTCBB: RGIN) Hotstocked.com Company Research
General Sentiment
RGIN stock has just formed a dangerous chart pattern breaking through support levels that can push the stock down further from here.
52 Week Price History
Price History
Calendar Year 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
High Price N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Low Price N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Year End Price N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Price Performance
RGIN share prices have been a strong downtrend while selling pressure seems to have slowed, there are no indicators suggesting this stock will go higher.
Time Period Actual Change Percent Change vs. S&P 500
4 Week - N/A N/A N/A N/A
13 Week - N/A N/A N/A N/A
26 Week - N/A N/A N/A N/A
52 Week - N/A N/A N/A N/A
Year To Date 0.1 16.7% 16.7%
Charts
Jan 31, 2011 Page 5

6. Regenicin, inc. (OTCBB: RGIN) Hotstocked.com Company Research
Description
Employee Warning! - You are seeing this warning here on the report because our research has determined that this company is probably
understaffed. There are currently only 7 working at this company. This is not sufficient to operate a successful public enterprise and can
hinder the company's development.
Low Priced Stock Warning - As of the last time we checked this stock was under $1.00 adding a high level of additional risk. We
recommend that only experienced investors even consider this stock, and to proceed with extreme caution.
Regenicin, Inc. is a biotechnology company specializing in the development of and commercialization
of regenerative cell therapies to restore the health of damaged tissues and organs. Regenicin, which was
founded in 2010, has assembled a world class team with a proven track record for developing and
bringing innovative medical devices and biotechnology products to market. Regenicin is playing a
critical role in developing an exciting breakthrough technology that uses the patient's own skin cells to
generate living, tissue-engineered skin for the treatment of chronic burns.
Jan 31, 2011 Page 6